Soudijn Willem, Van Wijngaarden Ineke, IJzerman Ad P
Division of Medicinal Chemistry Leiden/Amsterdam Center for Drug Research Leiden University PO Box 9502, 2300RA Leiden, The Netherlands.
Drug Discov Today. 2004 Sep 1;9(17):752-8. doi: 10.1016/S1359-6446(04)03220-9.
Allosteric modulation of G protein-coupled receptors has recently been recognized as an alternative approach to gain selectivity in drug action. In this overview, allosteric modulators that enhance or diminish the effects of (endogenous) agonists or antagonists on a variety of G protein-coupled receptors are described. Emphasis is placed on the latest developments in this research area, including data on the first clinical studies. It appears that all three major classes of G protein-coupled receptors (A, B and C) are amenable to allosteric modulation by small molecules. This constitutes an attractive and novel means to identify new leads in the drug discovery process. However, it requires a re-engineering of the majority of current assays. Finally, it is suggested to introduce the term 'non-competitive agonism' or 'allosteric agonism' next to allosteric modulation.
G蛋白偶联受体的变构调节最近被认为是一种在药物作用中获得选择性的替代方法。在本综述中,描述了增强或减弱(内源性)激动剂或拮抗剂对多种G蛋白偶联受体作用的变构调节剂。重点在于该研究领域的最新进展,包括首批临床研究的数据。似乎所有三大类G蛋白偶联受体(A、B和C类)都适合小分子的变构调节。这构成了药物发现过程中识别新先导物的一种有吸引力的新方法。然而,这需要对大多数现有检测方法进行重新设计。最后,建议在变构调节之外引入“非竞争性激动作用”或“变构激动作用”这一术语。